FDA Yanks Approvals for 18 Unused Drugs from Shelves
Published Date: 4/9/2025
Notice
Summary
The FDA is officially pulling the plug on 18 drug approvals because the companies told them these medicines aren’t being sold anymore. This means those drugs won’t be available, but no one’s losing money or access since they’re already off the shelves. If you’re involved with these drugs, now’s the time to update your records and plans!
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20085, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program
The FDA is asking for public feedback by November 2, 2026, on its Voluntary Improvement Program (VIP), which helps medical device makers improve quality through third-party reviews. This program supports better products and safer devices without adding extra costs or deadlines for companies. It’s all about encouraging excellence and teamwork between the FDA, industry, and partners like the Medical Device Innovation Consortium.
Previous / Next Documents
Previous: 2025-06044, Determination That ETHYOL (Amifostine) for Injection, 500 Milligrams/Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA checked and confirmed that ETHYOL (amifostine) 500 mg injection wasn’t taken off the market because of safety or effectiveness problems. This means drug companies can keep making and selling generic versions of ETHYOL as long as they follow the rules. Patients and healthcare providers can keep counting on this medicine without any interruptions or extra costs.
Next: 2025-06046, Determination That DECADRON (Dexamethasone Sodium Phosphate) Solution/Drops, Equivalent to 0.1 Percent Phosphate, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA says DECADRON eye drops (0.1% phosphate) weren’t pulled from shelves because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions, so patients and pharmacies won’t face shortages or price hikes. Everyone who uses or sells this medicine can breathe easy—no sudden changes or costs coming!